Acalabrutinib Chronic Lymphocytic Leukemia trial
A new phase 2 trial, NCT07582159, adds acalabrutinib to tafasitamab and venetoclax in CLL/SLL; BioQ shows its BTK potency and 121 registered trials.
BioQ Blog
Every BioQ post about ClinicalTrials.gov: real search results, sources and the query to repeat it.
A new phase 2 trial, NCT07582159, adds acalabrutinib to tafasitamab and venetoclax in CLL/SLL; BioQ shows its BTK potency and 121 registered trials.
One query, EGFR gefitinib, returns IC50 binding measurements, trial counts and CIViC evidence for the pair from three resources, as of 2026-11-06.